Malignant Tumors of the Thyroid
Clinical Concepts and Controversies
Seiten
2011
|
Softcover reprint of the original 1st ed. 1992
Springer-Verlag New York Inc.
978-1-4613-9129-6 (ISBN)
Springer-Verlag New York Inc.
978-1-4613-9129-6 (ISBN)
Thyroid carcinoma is an uncommon malignan ing the available non-human lines, as models cy. Third, the The answer is probably directly dependent very nature of the benign clinical course has suggested to the major health research fund on the very benign nature of most thyroid ing agencies that thyroid cancer is not worthy maligllancies.
Thyroid carcinoma is an uncommon malignan ing the available non-human lines, as models cy. In the vast majority of patients, if treated for cell cycle studies and oncogene/anti appropriately, it is associated with a benign oncogene regulation, because they are unaware clinical course. Why then does it hold a con of the often fundamental dichotomy between tinuing fascination for so many physicians? thyroid malignancy and prognosis. Third, the The answer is probably directly dependent very nature of the benign clinical course has suggested to the major health research fund on the very benign nature of most thyroid ing agencies that thyroid cancer is not worthy maligllancies. While there are terrible excep of study in a time of scarce resources. tions, the follicular and papillary thyroid can Nothing could be further from the truth. cers behave in a way quite alien to "common" This gratifying clinical course is the very reason neoplasia, since they grow and metastasize why the study of human thyroid cancer has the slowly. We believe that if only we could under potential for contributing further to our fun stand such a transformed state, we would be able to learn a great deal about the normal and damental understanding of malignancy and, abnormal regulation of the cell cycle and im perhaps more importantly, the mechanisms by prove our understanding of cancer. which the human body can resist neoplastic However, recent advances in the biology of cells.
Thyroid carcinoma is an uncommon malignan ing the available non-human lines, as models cy. In the vast majority of patients, if treated for cell cycle studies and oncogene/anti appropriately, it is associated with a benign oncogene regulation, because they are unaware clinical course. Why then does it hold a con of the often fundamental dichotomy between tinuing fascination for so many physicians? thyroid malignancy and prognosis. Third, the The answer is probably directly dependent very nature of the benign clinical course has suggested to the major health research fund on the very benign nature of most thyroid ing agencies that thyroid cancer is not worthy maligllancies. While there are terrible excep of study in a time of scarce resources. tions, the follicular and papillary thyroid can Nothing could be further from the truth. cers behave in a way quite alien to "common" This gratifying clinical course is the very reason neoplasia, since they grow and metastasize why the study of human thyroid cancer has the slowly. We believe that if only we could under potential for contributing further to our fun stand such a transformed state, we would be able to learn a great deal about the normal and damental understanding of malignancy and, abnormal regulation of the cell cycle and im perhaps more importantly, the mechanisms by prove our understanding of cancer. which the human body can resist neoplastic However, recent advances in the biology of cells.
1. Papillary Thyroid Carcinoma.- 2. Follicular Carcinoma of the Thyroid.- 3. Radiation-Induced Thyroid Carcinoma.- 4. Thyroid Cancer in the Pediatric Patient.- 5. Surgery for Well-Differentiated Thyroid Carcinoma.- 6. Thyroglobulin.- 7. Radioactive Iodine Treatment of Thyroid Carcinoma.- 8. Medullary Carcinoma of the Thyroid.- 9. Anaplastic Thyroid Carcinoma.- 10. Lymphoma of the Thyroid Gland.- 11. Carcinoma Metastatic to the Thyroid Gland.- 12. External Radiation Treatment for Thyroid Carcinoma.- 13. Chemotherapy of Advanced Thyroid Cancer.
Vorwort | T.F. Davies |
---|---|
Zusatzinfo | XIV, 218 p. |
Verlagsort | New York, NY |
Sprache | englisch |
Maße | 178 x 254 mm |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Chirurgie |
Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie | |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie | |
Schlagworte | Chirurgische Onkologie • Schilddrüsenkrebs |
ISBN-10 | 1-4613-9129-6 / 1461391296 |
ISBN-13 | 978-1-4613-9129-6 / 9781461391296 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
50,00 €